How Dr. Daniel Laby of SportsVision NYC Created a Whole Category of Moneyball for Vision

 

Do athletes have a sixth sense when it comes to anticipating a penalty kick or deciphering whether to swing at an iffy strike zone pitch? Yes and no — it’s a mix of stellar hand-eye coordination, past experience that helps athletes anticipate the ball, and training. But not simply athletic training; visual-motor reaction time training.

On this episode of the MarketScale Sports and Entertainment Podcast, host Shelby Skrhak sits down with Dr. Daniel Laby, a board-certified Ophthalmologist and founder of SportsVision NYC, to discuss a very “Moneyball” approach to the role of vision in sports and performance, as well as to break down the Reflexion technology powering neuro-fitness in sports.

“Our eyes are just a camera,” Laby said. “Our brain is what takes that image and makes a decision to bring in memory and training to decide whether you’re going to make a motor action.”

Laby began measuring eye-hand visual-motor reaction time more than 20 years ago when he was completing a fellowship with the LA Dodgers. Over 18 seasons, Laby measured the reaction time of thousands of baseball players and was able to quantify that data into actionable information coaches could use.

Over time, Laby went on to measure athletes’ vision in other sports and found correlations between specific sports and its athletes’ depth perception, contrast, and perception of light.

“Every sport has a different constellation of vision skills to perform optimally,” Laby said. “In baseball, for example, it has to do with how well do you see sharpness of vision and ability to see contrast.”

For the latest news, videos, and podcasts in the Software & Electronics Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!
Twitter – @TechMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More